Published in Aging and Elder Health Week, May 28th, 2006
The reduction in force was largely focused in areas primarily dedicated to the planned commercialization of Veronate, the company's most advanced product candidate.
In April 2006, the company announced that a pivotal phase III clinical trial of Veronate for the prevention of hospital-associated infections in premature, low-birth-weight infants failed to meet its primary or secondary endpoints.
"We have taken immediate steps to reduce and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.